PMID- 35090303
OWN - NLM
STAT- MEDLINE
DCOM- 20220204
LR  - 20220420
IS  - 2008-823X (Electronic)
IS  - 1028-852X (Print)
IS  - 1028-852X (Linking)
VI  - 26
IP  - 2
DP  - 2022 Mar 1
TI  - Sustained Release of Risedronate from PLGA Microparticles Embedded in Alginate 
      Hydrogel for Treatment of Bony Lesions.
PG  - 124-31
LID - 10.52547/ibj.26.2.124 [doi]
AB  - BACKGROUND: Inflammatory bone resorption in periodontitis can lead to tooth loss. 
      Systemic administration of bisphosphonates such as risedronate for preventing 
      bone resorption can cause adverse effects. Alginate hydrogel (ALG) and poly 
      (lactic acid-co-glycolic acid) (PLGA) microparticles have been studied as drug 
      delivery systems for sustained release of drugs. Therefore, the release pattern 
      of risedronate from PLGA microparticles embedded with ALG was studied as a drug 
      delivery system for sustained release of the drug, which can be used in local 
      administrations. METHODS: Risedronate-containing PLGA microparticles were 
      fabricated using double emulsion solvent evaporation technique. Ionic 
      cross-linking method was used to fabricate risedronate-loaded ALG. 
      Risedronate-containing PLGA microparticles were then coated with ALG. The 
      calibration curve of risedronate was traced to measure encapsulation efficiency 
      (EE) and study the release pattern. Scanning electron microscope (SEM) imaging 
      was carried out, and cell toxicity was examined using MTT assay. Statistical 
      analysis of data was carried out using SPSS ver. 20 software, via one-way ANOVA 
      and Tukey's tests. RESULTS: SEM imaging showed open porosities on ALGs. The mean 
      EE of PLGA microparticles for risedronate was 57.14 +/- 3.70%. Risedronate released 
      completely after 72 h from ALG, and the cumulative release was significantly 
      higher (p = 0.000) compared to PLGA microspheres coated with ALG, which 
      demonstrated sustained released of risedronate until day 28. Risedronate-loaded 
      ALG showed a significant decrease in gingival fibroblasts cell viability (p < 
      0.05). CONCLUSION: Alginate-coated PLGA microspheres could release risedronate in 
      a sustained and controlled way and also did not show cell toxicity. Therefore, 
      they seem to be an appropriate system for risedronate delivery in local 
      applications.
FAU - Azari, Ghazaleh
AU  - Azari G
AD  - Faculty of Dentistry, Tehran Medical Sciences, Islamic Azad University, Tehran, 
      Iran.
FAU - Aghayan, Shabnam
AU  - Aghayan S
AD  - Department of Periodontology, Faculty of Dentistry, Tehran Medical Sciences, 
      Islamic Azad University, Tehran, Iran.
FAU - Seyedjafari, Ehsan
AU  - Seyedjafari E
AD  - Department of Biotechnology, College of Sciences, University of Tehran, Tehran, 
      Iran.
LA  - eng
PT  - Journal Article
DEP - 20220301
PL  - Iran
TA  - Iran Biomed J
JT  - Iranian biomedical journal
JID - 9814853
RN  - 0 (Alginates)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Hydrogels)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - KM2Z91756Z (Risedronic Acid)
SB  - IM
MH  - Alginates/*chemistry
MH  - Bone Diseases/*drug therapy
MH  - Cell Line
MH  - Delayed-Action Preparations/metabolism
MH  - Hydrogels/chemistry
MH  - Microspheres
MH  - Polylactic Acid-Polyglycolic Acid Copolymer/*chemistry
MH  - Risedronic Acid/*metabolism
PMC - PMC8987410
OTO - NOTNLM
OT  - Alginates
OT  - Hydrogels
OT  - Polylactic acid-polyglycolic acid copolymer
OT  - Risedronic acid
COIS- None declared.
EDAT- 2022/01/30 06:00
MHDA- 2022/02/05 06:00
PMCR- 2022/03/01
CRDT- 2022/01/29 01:47
PHST- 2022/11/14 00:00 [aheadofprint]
PHST- 2022/01/29 01:47 [entrez]
PHST- 2022/01/30 06:00 [pubmed]
PHST- 2022/02/05 06:00 [medline]
PHST- 2022/03/01 00:00 [pmc-release]
AID - 10.52547/ibj.26.2.124 [doi]
PST - epublish
SO  - Iran Biomed J. 2022 Mar 1;26(2):124-31. doi: 10.52547/ibj.26.2.124.